UroAlert - GU Oncology Weekly

November 12, 2025

Videos

Peer-to-Peer Clinical Conversations

Survival Gap in Latin American Cancer Care: Public vs Private Systems - Fernando Maluf

Fernando Maluf

Fernando Maluf joins Ashish Kamat to discuss data examining healthcare disparities in Latin America using a São Paulo database of over 6,000 bladder cancer patients.

Shifting from Surgery to Chemoablation for Low-Grade Bladder Cancer Treatment - Katie Murray

Katie Murray

Zachary Klaassen is joined by Katie Murray to discuss chemoablation with mitomycin (ZUSDURI™) for low-grade intermediate-risk non-muscle invasive bladder cancer.

Beyond the Abstracts

HLA Class I Expression Shapes the Tumor Immune Microenvironment and Influences Prognosis in Prostate Cancer - Beyond the Abstract

ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-Label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-Naive High-Risk, Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

Urinary Organs-at-Risk for Radiotherapy Following Radical Prostatectomy: Contouring Guidelines on Behalf of the Francophone Group of Urological Radiation Therapy (GFRU) - Beyond the Abstract

Evaluating Surrogates for Overall Survival in the Adjuvant Treatment of Bladder Cancer with Chemotherapy - Beyond the Abstract

Theranostics 2.0: Target-Driven, Artificial Intelligence-Enabled Cancer Therapy Across Tumor Types - Beyond the Abstract

Detection of Genome-Wide Methylation Changes in Bladder Cancer by Long-Read Sequencing of Urinary DNA - Beyond the Abstract

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

HER2 and urothelial carcinoma: current understanding and future directions.

Survival According to Source of Treatment Funding in Bladder Cancer: Analysis of a Large Public Database From São Paulo, Brazil.

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials.

Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.

Urothelial carcinoma and the potential clinical application of urinary extracellular vesicles: Current Status and prospects.

Evaluation of the utility of molecular subtype classification by immunohistochemistry in bladder cancer undergoing radical cystectomy: a retrospective cohort study.

Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer.

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.

Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.

Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis.

Nectin-4 in bladder cancer: biology and predictive biomarker potential.

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-Label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-Naive High-Risk, Non-Muscle Invasive Bladder Cancer - Beyond the Abstract

UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma.

Real-world impact of cisplatin-based neoadjuvant chemotherapy on bladder cancer survival: a 20-year study.

Trends in the Diagnoses of Subtype Histologies in Bladder Cancer - Expert Commentary

Penile & Urethral Cancers

Centralization or individualization in penile cancer care : Evidence, international insights, and a future framework for Germany.

Radiotherapy for penile cancers: 2025 update.

Local recurrence after glans-sparing surgery: no impact on penile cancer-specific survival.

Renal Cancer

Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomes.

Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.

Tyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.

Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology.

Heterogeneous expression of BMP7, HIF-2α, Ki-67, and E-Cadherin in clear cell renal carcinoma: Prognostic implications based on tumor region.

Impact of Hemoglobin A1c on the Obesity Paradox and Survival in Patients With Non-Metastatic Renal Cell Carcinoma.

PSMA PET/CT Incidental Detection of Tumor Thrombus From Unsuspected Renal Cell Carcinoma and Comparison with FDG PET/CT.

Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples.

Sarcomatoid dedifferentiation as a predictor of overall mortality in surgically treated metastatic renal cell carcinoma.

Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.

Lower SYNJ2BP Gene Expression Is Associated With Poor Survival Outcome and Treatment Response in Clear Cell Renal Cell Carcinoma: A Bioinformatics Analysis.

Prostate Cancer

HLA Class I Expression Shapes the Tumor Immune Microenvironment and Influences Prognosis in Prostate Cancer - Beyond the Abstract

Truqap Combination in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer Demonstrated Statistically Significant and Clinically Meaningful Improvement in Radiographic Progression-Free Survival in CAPItello-281 Phase III Trial

New USC Study Identifies Key Genes Linked to Aggressive Prostate Cancer in People of African Descent

Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.

Factors Associated with Early Detection of Clinically Significant Prostate Cancer After a Negative MRI-Informed Biopsy.

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Virtual versus in-person sexual rehabilitation for prostate cancer survivors: a retrospective cohort study comparing the Prostate Cancer Rehabilitation Clinic (PCRC) and the True North Sexual Health and Rehabilitation eClinic (SHAReClinic).

Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.

Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer.

Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

Classification of Inaccurate Information About Prostate Cancer on Social Media in English and Spanish.

Evaluation of PI-RADS version 2.1 vs. 2.0 for detecting clinically significant prostate cancer in biopsy-naïve men.

Salvage Stereotactic Body Radiation Therapy for Locally Recurrent Prostate Cancer: Quality of Life Outcomes from a Prospective Clinical Trial.

Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway.

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.

PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?

Artificial intelligence-based lesion characterization and outcome prediction of prostate cancer on [18F]DCFPyL PSMA imaging.

Clinical and MRI variables in decision support systems for prostate MRI: A systematic review of decision support tools, nomograms, and risk models.

Black Men's Prostate Cancer Knowledge, Attitudes, Beliefs, and Access to Health Information.

ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.

A Multi-Center Comparative Analysis of the G8-Score and Charlson Comorbidity Index as General Health Assessment Tools in Older Patients With Prostate Cancer.

Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.

Management of high-risk prostate cancer in Spain: results from a national patterns of care survey.

Unlocking New Therapeutic Strategies in Oligometastatic Prostate Cancer with Radioligand and Metastasis-directed Radiation Therapy.

Beyond PSA: The Future of Prostate Cancer Diagnosis Using Artificial Intelligence, Novel Biomarkers, and Advanced Imagery.

Index Cancer Density Is a Stronger Predictor of Pelvic Lymph Node Invasion than Percentage of Biopsy-Positive Cores in EAU High-Risk Prostate Cancer: Clinical Impact in 254 Patients Treated and Staged with Robot-Assisted Radical Prostatectomy.

Increasing Phytochemical-rich Foods and Lactobacillus Probiotics in Men with Low-risk Prostate Cancer-A Randomised, Double-blind, Placebo-controlled Trial.

Upper Tract Tumors

Genotype-Phenotype Characterization of Lynch Syndrome-associated Upper Tract Urothelial Carcinoma.

Testicular Cancer

Primary Retroperitoneal Lymph Node Dissection in Marker Positive Clinical Stage II Non-Seminomatous Germ Cell Tumours.

Validation of the Testicular Health Outcomes Report (THOR): a testicular cancer health-related quality of life instrument.

Lifetime occupational and para-occupational exposure to organic solvents and testicular germ cell tumor risk: a French case-control study-TESTIS.

Cannabis use and risk of testicular germ cell tumour: a systematic review and meta-analysis.

Testicular Cancer Education-Hidden Potential Ways to Improve Awareness and Early Diagnosis in Young Men?

Role of Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Seminoma: Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC